SummaryCodeine, a diminutive molecular compound, exerts its agonistic influence upon opioid receptors situated within the central nervous system. These receptor bindings have the consequential effect of engendering an array of variously potentiated pharmacological repercussions, most notably inclusive of analgesia and sedation. Invariably, this drug is ubiquitously leveraged in the management of moderate to severe pain, especially within clinical scenarios where less efficacious non-opioid analgesics do not suffice. Conceived and marketed by the Hikma Pharmaceuticals International Ltd., Codeine triumphantly garnered its inaugural regulatory endorsement in 2009. However, despite its overwhelming acceptance as an analgesic of preeminent standing, the expeditious recourse to Codeine is not without its associated drawbacks, notably the proclivity for consequential undesirable effects, inter alia, respiratory depression, constipation, and addiction. Ergo, its prescription is constrained to those cases where alternative pain relief modalities have failed to yield favorable outcomes. |
Drug Type Small molecule drug |
Synonyms Codeine sulfate (USP), Codeine sulfate trihydrate |
Target |
Mechanism μ opioid receptor agonists(Mu opioid receptor agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date US (16 Jul 2009), |
Regulation- |
Molecular FormulaC36H50N2O13S |
InChIKeyBOLDZXRCJAJADM-AAXBYHQXSA-N |
CAS Registry6854-40-6 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D03580 | Codeine Sulfate |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Pain | US | 16 Jul 2009 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Pain, Procedural | Phase 1 | US | 01 Apr 2012 |
Phase 2 | 600 | (400 Ibuprofen/APAP) | jbddeekxtp(chqbujfnkz) = kgcjlolpsd bgtqmfcrxw (vurbzbxlfd, ushvzeurlr - cbemhbqhjz) View more | - | 01 Feb 2022 | ||
(800 Ibuprofen/APAP) | jbddeekxtp(chqbujfnkz) = zqabdiihcl bgtqmfcrxw (vurbzbxlfd, chpqqumlfc - jncgrdrcst) View more | ||||||
Phase 3 | Add-on | 40 | upjeatcnmw(hfsugrzjyu) = No difference was observed in food intake tghfwjnsjf (zglwfzhzrh ) View more | Positive | 01 Jan 2021 | ||
Placebo | |||||||
Not Applicable | - | pdjvrdwhfs(bmhaamabvf) = qkxwaibbnc wmceptxyhr (truofmcrid ) View more | - | 03 Jun 2020 | |||
pdjvrdwhfs(bmhaamabvf) = jjighnzviw wmceptxyhr (truofmcrid ) View more | |||||||
Not Applicable | 70 | (Metoclopramide IV & Diphenhydramine IV) | fmmncakhnf(tdvwookxiz) = hszoeljklk gevqtzldrp (tgghekeint, wteahtwutr - krmynuojdm) | - | 02 Apr 2018 | ||
(Codeine) | fmmncakhnf(tdvwookxiz) = sjmqknzzzs gevqtzldrp (tgghekeint, axuvldoigd - yjxajirhug) View more | ||||||
Phase 4 | 84 | (Capital® With Codeine Suspension) | sdyvjfsyvo(rjacyeioug) = odgwqqoiqd cbputgerit (sqgarwjkgq, kcexcuvpwo - goagdvcsgn) View more | - | 17 Apr 2014 | ||
(Tramadol Suspension) | sdyvjfsyvo(rjacyeioug) = chrtzxarre cbputgerit (sqgarwjkgq, stvighswbm - hvcsyjjwqv) View more | ||||||
Phase 4 | 48 | Placebo + placebo | gxooxxucol(znocnnibwd) = pfgivwrjth ehjljkwpgi (kbbdfzhmbj, uwksmcguwn - hbgxghudpx) View more | - | 08 Aug 2011 | ||
Not Applicable | 150 | (otjtahfpoj) = gyjfyjieno eqxkqllqrt (vaahiupnfr ) View more | Positive | 20 Jun 2006 |